Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC.
Eun Ji LeeSeung Yeon OhYou Won LeeJu Young KimMin-Je KimTae Ho KimJii Bum LeeMin Hee HongSun Min LimAnke BaumLydia WoelflingsederHarald EngelhardtMark PetronczkiFlavio SolcaMi Ran YunByoung Chul ChoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our findings highlight the potential of BI-4732, a selective EGFR-TKI with high BBB penetration, targeting a broad range of EGFR mutations, including C797S, warranting clinical development.